As angiotensin converting enzyme inhibitors are becoming increasingly popular in the treatment of hypertension, their role in the management of hemodialysis patients requires further definition. On theoretical grounds their role could be limited because hypertension in most dialysis patients is determined largely by volume expansion (1) (2) (3) (4) ; and there have also been suggestions that as a group these patients may be more vulnerable to the side effects of this class of drugs. In recent years several agents have become available, since the initial reports that a peptide isolated from the venom of a Brazilian pit viper could potentiate bradykinin and inhibit converting enzyme (5-7). The first agent, tepratide, administered intravenously to hypertensive subjects in 1974 (8), was later followed by captopril, now widely used; and enalapril, a newer compound, is now undergoing clinical trials (9) .
All of these drugs inhibit the non-specific dicarboxypeptidase which converts angiotensin I to the potent vasoconstrictor angiotensin II and also degrades the vasodilator bradykinin. The lowered angiotensin II levels decrease aldosterone production and also promote a reflex increase in plasma renin levels (10) (11) (12) . Bradykinin, which releases vasoactive prostaglandins, may be increased, an effect attenuated by indomethacin (13, 14) . Circulating levels of norepinephrine are unchanged, as is the response of plasma norepinephrine to the upright position (10) (11) (12) . Thus, by lowering peripheral vascular resistance, these agents are thought to be of benefit not only in hypertension but also in other clinical states such as congestive heart failure (15) .
Captopril, (D-3-mercapto-2-methyl-L-proline), the first agent available for oral use, is rapidly absorbed from the gastrointestinal tract, and peak blood levels are obtained in thirty to ninety minutes. In the fasting state some 75 per cent of the drug is absorbed, but with food the absorption is decreased by 30 to 40 per cent. Captopril is thirty per cent protein bound and is distributed in most tissues except the central nervous system. In patients with normal renal function, the half life is about two hours, and 50 per cent of the drug appears in the urine in the first four hours (10) (11) (12) . In renal failure, the half life of 62 captopril and its metabolites increases, and less of the unchanged drug and more of its metabolites (chiefly mixed disulfides of endogenous sulfhydryl containing compounds) are present in the serum (16) (17) . In patients not yet on dialysis the clearance approximates the creatinine clearance, and modified dosage regimens have been suggested (16, 17) . Hemodialysis removes a significant proportion of the drug. Using hollow fiber cuprophane membrane dialyzer with a 1.25 m 2 surface area, Kirakata et al noted the clearance of captopril to be 80 ml per minute, compared with urea and creatinine clearances of 144 and 123 (18) .
Adverse effects reported with captopril include rash, pruritus, eosinophilia, taste impairment, and proteinuria with membranous glomerulonephritis (10) (11) (12) 19) . Decreases in neutrophil count to less than 300/mm 2 have been reported in 0.3 per cent of all patients, usually in the third week of therapy; patients with renal failure represented 88 per cent of this group (20) . The sulfhydryl group on the molecule has been thought by some to be associated with these side effects.
Enalapril, a newer converting enzyme inhibitor with similar pharmacological properties, is chemically an N-carboxymethyl dipeptide rather than a mercaptan, and is an ester which must be deesterified for absorption as the active diacid compound (21) . Enalapril crosses the blood brain barrier poorly. Its principal route of excretion is renal, with a small biliary component. Unlike captopril, enalapril has a slower onset and longer duration of action, the converting enzyme inhibition persisting for up to twentyfour hours (22) . Being long acting and potentially free from side effects, it may prove to be of considerable value. It is currently undergoing clinical trials in hernodialvsis patients.
As captopril has been available longer, several groups have reported the successful use of this drug in short term studies of hemodialysis patients whose volume status was well controlled. Although the hypotensive effect of captopril does not strictly correlate with the height of plasma renin activity, it appears that the drug is extremely effective in patients with high renin activity at their dry weight. In one such patient Vaughan et al reported considerable hypotension persisting for twenty four hours after a single 10 mg dose (23) . In patients with low renin activity Wauters et al., found it necessary to add salt substraction (ultrafiltration with replacement with dextrose and water) for the hypotensive effect of captopril to be manifested (24) . In anephric patients, who by definition have low plasma renin activity. Case et al did not find a decrease in blood pressure in the five anephric patients they studied (25) . In another study (double blind, of seven anephric patients) captopril reduced the blood pressure only in the first twenty four hours after hemodialysis -ultrafiltration, but not two days later when the same patients were studied in the fluid replete state (26). It therefore appears that the activity of the renin-angiotensin axis is an important predictor of the hypotensive response of captopril.
The immediate hypotensive effect of captopril in chronic hemodialysis patients, however, may be unrelated to interference with the renin-angiotensin system. In a group of well dialysed patients, Iseki et al found that the decrease in mean arterial pressure at one and three hours after the administration of captopril, which correlated with a decrease in total peripheral resistance index, did not correlate with an increase in plasma renin activity (27). Moreover, the same authors found that blood pressure may be reduced with captopril in patients who fail to respond to (Sar, lieu), a specific angiotensin II antagonist (28), suggesting that the bradykinin system may be involved in the immediate response to captopril.
It is well recognized that most dialysis patients have a water and salt dependent hypertension and that only a few remain hypertensive after adequate ultrafiltration. In clinical practice, however, many patients require antihypertensive drugs because they are not capable of restricting their water and salt intake. Since angiotensin II is known to stimulate thirst (29), converting enzyme inhibition may conceivably help the patients to drink less by suppressing thirst. This may present an advantage over direct vasodilating agents such as hydralazine and minoxidil which increase angiotensin levels. In view of reports that renin may increase erythropoesis (30) perhaps these agents may also have a beneficial effect on anemia. It is evident that further experience with these agents is needed in the long term treatment of hemodialysis patients.
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When blood is exposed to synthetic dialysis membranes the plasma proteins are adsorbed on their surface, leading to the activation of the coagulation, complement, kinin, and fibrinolytic systems. Thrombin in its active form adheres to the membranes and eventually gives rise to a while mural thrombus composed mainly of fibrin, platelets and leukocytes (1, 2) . The inactivation and denaturation of the coagulation inhibitory factors also facilitate the deposition of thrombin, as do the changes occuring when platelets and white blood cells come in contact with the membranes. All this tends to reduce the efficiency of the dialyser by decreasing its effective surface area and by altering the permeability of the membrane through protein coating. It may also cause difficulties in reusing dialysers, as well as possible embolisation from the dislodgement of a thrombus (1). Anticoagulation is currently used routinely to prevent the formation of clots in the dialyser, and is achieved through the use of heparin. Easily available and inexpensive, heparin has a rapid onset and a short duration of action (3). It acts by forming a complex with antithrombin III, which inactivates several coagulation factors including thrombin. Anticoagulation is monitored by periodic measurements of the whole blood clotting time during dialysis. In general, heparin is well tolerated and devoid of serious consequences. It may, however, cause hemorrhagic complications such as gastrointestinal bleeding, subdural hematoma, hemopericardium, retroperitoneal hematoma, bloody pleural effusion, bleeding at surgical sites, hemorrhage into joints, occular and retinal bleeding, and menorrhagia (4-6). These complications make heparin a less than ideal anticoagulant, especially in uremic patients with underlying coagulopathy. Paradoxically, heparin may also potentiate a thromboembolic tendency by decreasing levels of antithrombin III, a cofactor which is consumed during heparin therapy (3) . Thrombocytopenia occurs frequently (3), partly from increased platelet aggregation (7) and partly from antiplatelet antibody production. This further aggravates the
